Familial childhood-onset progressive cerebellar syndrome associated with the ATP1A3 mutation
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 13, 2016
- Accepted in final form February 21, 2017
- First Published March 27, 2017.
Author Disclosures
- Fatima Jaffer, MRCP,
- Katherine Fawcett, PhD,
- David Sims, PhD,
- Andreas Heger, PhD,
- Henry Houlden, FRCP,
- Michael G. Hanna, FRCP,
- Helen Kingston, PhD and
- Sanjay M. Sisodiya, FRCP
- Fatima Jaffer, MRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katherine Fawcett, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Sims, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) MRC, H4R00700, 2016-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Heger, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Genomics plc, Senior Data Engineer (Manager), 1.5
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henry Houlden, FRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My laboratory is funded by: The Medical Research Council (MRC) UK, The BRT, The MDA USA, Muscular Dystrophy UK, Rosetrees Trust, The Wellcome Trust and the National Institute for Health (NIHR) UCL/UCLH BRC.Research (NIHR) UCLH/UCL Biomedical Research Centre.
NONE
My laboratory is funded by: The Dystonia Medical Research Foundation (DMRF), The Parkinson's Disease Foundation (PDF), National Organisation for Rare Disorders (NORD) and The Brain Research Trust (BRT). The National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre.
NONE
NONE
NONE
NONE
NONE
NONE
- Michael G. Hanna, FRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
novartis
NONE
NONE
NONE
NONE
NONE
NONE
(1) MRC Centre Grant, MR/K000608/1. (2) The Myositis Support Group.
NONE
NONE
NONE
NONE
NONE
NONE
- Helen Kingston, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sanjay M. Sisodiya, FRCP
NONE
NONE
(1) UCB Pharma, honoraria(2) Eisai, honorarium(3) Nutricia, honorarium
(1) Epileptic Disorders, Editorial Advisory Board, 2014-(2) Practical Neurology, Editorial Advisory Board, 2015-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) UCB Pharma
(1) NIH, co-investigator, 2015-2019(2) European Commission, 602102 (EPITARGET),co-investigator, 2013-2018
(1) Wellcome Trust(2) European Commission
(1) Epilepsy Action (2) Dravet Syndrome UK
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurosciences (F.J.), King's College Hospital, London; MRC Centre for Neuromuscular Diseases and Department of Molecular Neuroscience (F.J., H.H., M.G.H.), UCL Institute of Neurology; MRC Computational Genomics Analysis and Training Programme (K.F., D.S., A.H.), University of Oxford; Central Manchester University Hospitals (H.K.); and NIHR UCLH Biomedical Research Centre (S.M.S.), Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, UK.
- Correspondence to Prof. Sisodiya: s.sisodiya{at}ucl.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.